baricitinib + omeprazole

This is a **combination of baricitinib and omeprazole**, used experimentally or in research to assess potential pharmacokinetic interactions rather than as a fixed-dose coformulation. **Baricitinib** is a selective Janus kinase (JAK) 1 and 2 inhibitor primarily used for autoimmune and inflammatory diseases such as rheumatoid arthritis, severe alopecia areata, and has been authorized for COVID-19 in hospitalized adults. Its mechanism of action is the inhibition of JAK1 and JAK2, preventing signal transduction of cytokines involved in immunology and inflammation. **Omeprazole** is a proton pump inhibitor (PPI) widely used to reduce stomach acid production for indications like gastroesophageal reflux disease, peptic ulcers, and related disorders. It acts by irreversibly inhibiting the H+/K+ ATPase (proton pump) in gastric parietal cells, leading to suppressed gastric acid secretion. The combination has been specifically studied to evaluate whether omeprazole-induced gastric pH changes affect the absorption and pharmacokinetics of baricitinib[2].

Brand names

Olumiant (baricitinib)Prilosec (omeprazole)Losec (omeprazole)

Other names

baricitinib + omeprazole